Dispensary Corner 29 Aug 25
THE midlife crisis is a thing of a past, new research has uncovered, and while that is worth celebrating, the…
First Nations cancer resources
BRISTOL Myers Squibb (BMS) Australia has launched new, culturally appropriate educational resources aimed to support First Nations Australians diagnosed with…
Sandoz workplace recognition
BIOSIMILAR and generic medicines company, Sandoz, has ranked tenth in the medium category for Best Workplaces in Australia in 2025,…
In the Spotlight
OUR Wednesday Product Spotlight page has become so popular that we have added another opportunity to feature your products on…
DTC menopause tests raise concerns
INTERNATIONAL experts have warned of a sharp increase in direct-to-consumer (DTC) menopause services offered by wellness practitioners and online suppliers,…
Qld Guild urges scope training
THE Pharmacy Guild of Australia, Queensland branch, is encouraging community pharmacists to enrol in the scope of practice training at…
PD for Fri 29 Aug 2025
Now is the time to enrol in scope training says Qld Guild, menopause hormone panels more harm than good, BMS…
PD breaking news – Wesfarmers Health FY25 earnings up 28%
Wesfarmers released its 2025 full-year results this morning, reporting a net profit after tax of $2,926 million. The group had…
Biedermann Medtech Group kondigt transformatie van Amerikaanse marktbenadering en nieuw bedrijfsmodel aan
MIAMI–(BUSINESS WIRE)–De Biedermann Medtech Group, de toonaangevende innovator op het gebied van volgende generatie spinale en extremiteit implantaatsystemen en procedurele…
Abemaciclib Plus Endocrine Therapy Improves Survival in Patients With HR+/HER2– Breast Cancer
Abemaciclib enhances overall survival in high-risk HR+, HER2– early breast cancer, establishing its role as a standard adjuvant therapy.